Navigation Links
Karolinska Development: EMEA Recommends Orphan Drug Designation for Acute Myeloid Leukemia Treatment
Date:2/18/2010

STOCKHOLM, February 18, 2010 /PRNewswire/ -- The European Medicines Agency (EMEA) recommends orphan drug status for Aprea's treatment of acute myeloid leukemia (AML). The treatment is currently undergoing a Phase I clinical study and a final decision from the European Commission regarding status is expected in a few weeks. Aprea is part of the Karolinska Development portfolio.

"Aprea is developing a new class of anticancer drugs for the treatment of acute myelogenous leukemia, the most common acute leukemia affecting adults which is currently lacking efficient treatment. An orphan drug status would significantly shorten the development time, lower development costs and, if approved, extend market exclusivity to the benefit of affected patients, Aprea and Karolinska Development," says Conny Bogentoft, CEO Karolinska Development.

Karolinska Development holds 43 percent of the Aprea share capital and votes. For further information about Aprea, please visit http://www.aprea.com.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe.

Using a unique, highly cost-efficient business model, the management team guides the commercialization of world-class life science innovations, helping to shape the next-generation pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects, 12 compounds are undergoing clinical trials. The portfolio also includes a total of 19 potential first-in-class products. http://www.karolinskadevelopment.com

    For more information, please contact:

    Conny Bogentoft, CEO Karolinska Development
    Tel: +46(0)706-88-61-43, e-mail:
    conny.bogentoft@karolinskadevelopment.com

SOURCE Karolinska Development AB


'/>"/>
SOURCE Karolinska Development AB
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Karolinska Development New Share Issue Completed - Raising 380 MSEK (36 MEUR)
2. Karolinska Development Portfolio Company Launches GMP Facility for Particulate Manufacturing
3. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
4. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
5. Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs
6. Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
7. Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
8. Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms
9. US Expert Panel Recommends the Use of Fractional Exhaled Nitric Oxide (FENO) in the Diagnosis and Management of Asthma
10. RiskMetrics Recommends Taro Shareholders Vote Against Taro Board of Directors
11. PROXY Governance Recommends Against Taros Board and Supports Sun
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
(Date:4/27/2016)... 27, 2016  Bayer Animal Health today announced ... the University of Florida College of Veterinary Medicine, ... in Communication Award (BECA). Brittany was selected from ... a total of $70,000 in scholarship funds through ... Bayer has provided a total of $232,500 in ...
(Date:4/27/2016)... , April 27, 2016 ... ), a developer of a new generation of ... positive overall survival results for Paclical/Apealea in the ... 789 patients with epithelial ovarian cancer. These preliminary ... Paclical/Apealea in combination with carboplatin versus Taxol in ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... The number of chronically and ... – meaning that there is an urgent need for highly skilled care managers and ... delivering a multi-pronged approach to train and retain care managers, and enhance their skills. ...
(Date:4/28/2016)... ... April 28, 2016 , ... The Dentists Insurance Company ... signed a letter of intent with Moda to acquire Dentists Benefits ... , Started by dentists 36 years ago, TDIC focuses exclusively on supporting the ...
(Date:4/28/2016)... ... April 28, 2016 , ... Head Over Heels Athletic Arts’ gymnast, Brooklyn ... competition will be held at the University of Montana on April 28-May 1. Varize ... Mississippi River. , In order to qualify, Varize needed to place top seven all-around ...
(Date:4/28/2016)... LIVONIA, MICH. & WASHINGTON, D.C., (PRWEB) , ... ... ... nation’s largest Catholic health systems, and the Campaign for Tobacco-Free Kids, a leading ... a new partnership to promote federal, state and local policies that can help ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Infrastructure Management solutions, announces today the availability of its latest software release, ... of capacity management and optimization, providing new analytical capabilities that assess complex ...
Breaking Medicine News(10 mins):